# Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients

> **NCT03276988** · PHASE1,PHASE2 · COMPLETED · sponsor: **Genexine, Inc.** · enrollment: 8 (actual)

## Conditions studied

- Total Thyroidectomy
- Near-total Thyroidectomy

## Interventions

- **DRUG:** Period 1 GX-30, Period 2 THYROGEN®
- **DRUG:** Period 1 THYROGEN®, Period 2 GX-30

## Key facts

- **NCT ID:** NCT03276988
- **Lead sponsor:** Genexine, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-09-07
- **Primary completion:** 2020-01-20
- **Final completion:** 2020-01-20
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2020-09-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03276988

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03276988, "Tolerability, Safety and Pharmacokinetics Study of GX-30 in Total Thyroidectomy or Near Total Thyroidectomy Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03276988. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*